Publications by authors named "Marjolein S Bruin-Weller"
Article Synopsis
- Atopic dermatitis (AD) significantly impacts patients' quality of life, and the Atopic Dermatitis Control Tool (ADCT) is used to measure how well it's being managed in adults.
- A study involving 863 participants revealed that 59% had controlled AD, while those with uncontrolled AD had higher symptom severity and were more likely to be using topical treatments only.
- The findings suggest that shifting treatment strategies from topical to systemic therapies might benefit patients struggling with uncontrolled AD symptoms.
Article Synopsis
- - The study evaluates the effectiveness and longevity of treatments (dupilumab, methotrexate, and cyclosporine A) for pediatric patients aged 2-17 with severe atopic dermatitis across five centers in the Netherlands from 2013-2023.
- - Out of 502 treatment episodes analyzed, dupilumab showed the highest drug survival rates over three years (84.1% at one year, 72.3% at two, and 62.0% at three), compared to significantly lower rates for methotrexate and cyclosporine A.
- - The main reason for discontinuing treatment was ineffectiveness, especially noted with cyclosporine A, while factors like treatment
Article Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
Article Synopsis
- Atopic dermatitis (AD) is commonly linked with asthma and allergic rhinitis (AR), and while dupilumab is an effective treatment for AD in children, its impact on these related conditions hasn't been well-studied.
- In this study, 84 pediatric patients receiving dupilumab were examined, revealing that 59.5% had asthma and 85.7% had AR at baseline, with various tests conducted to assess their health status.
- Results showed significant improvements after one year of treatment, including decreased levels of FeNO (indicating lowered airway inflammation) and reduced aeroallergen-specific IgE levels in patients with asthma and/or AR.
Article Synopsis
- Atopic dermatitis (AD) significantly impacts quality of life due to intense itching and other symptoms; this study investigates the effects of the oral medication upadacitinib on patients with moderate-to-severe AD over 16 weeks.
- The analysis included data from 1,683 patients in clinical trials, showing that those taking upadacitinib experienced notable improvements in itching and other quality of life indicators compared to those on a placebo, starting as early as one week and continuing through the study period.
- Results indicated that patients on upadacitinib reported better outcomes in areas like skin pain, sleep, daily activities, emotional well-being, and overall treatment satisfaction, suggesting this medication could be an effective option for managing AD
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Junfen Zhang Celeste M Boesjes Laura Loman Esmé Kamphuis Margreet L E Romeijn Marjolein S de Bruin-Weller
J Am Acad Dermatol
August 2024
Article Synopsis
- A study evaluated the effectiveness and safety of dupilumab for treating moderate-to-severe atopic dermatitis (AD) over a long-term period of up to 5 years, emphasizing patient-reported outcomes.
- Data from 1223 patients (1108 adults and 115 children) showed improved quality of life measures and work impairment in both groups after at least one year of treatment.
- Despite the treatment's favorable safety profile, including a 66.8% reporting rate of adverse events (most commonly conjunctivitis), there were significant amounts of missing data in reported outcomes, particularly in children.
Article Synopsis
- * Out of 103 patients, significant improvements were observed over 28 weeks, with high rates of reduction in eczema severity and itching.
- * While some patients discontinued due to ineffectiveness or adverse events (mainly nausea), abrocitinib showed effectiveness for those who previously did not respond to other treatments like dupilumab or upadacitinib.
Article Synopsis
- Prurigo nodularis is a chronic skin disease causing intense itching, and nemolizumab, an IL-31 receptor antagonist, targets its underlying mechanisms.* -
- In a phase 3 trial, 274 adults with moderate-to-severe prurigo nodularis were given nemolizumab or a placebo for 16 weeks, showing significant improvements in itch and overall skin condition.* -
- Results revealed that 56.3% of the nemolizumab group reported reduced itching compared to 20.9% in the placebo group, with similar trends observed for other secondary outcomes, demonstrating its efficacy (P<0.001).*
Article Synopsis
- The increased use of dupilumab for treating atopic dermatitis (AD) has led to reports of cutaneous T-cell lymphomas (CTCL) and related lymphoid infiltrates in patients.
- A study at the University Medical Center Utrecht analyzed adult patients with AD who were thought to have CTCL during dupilumab treatment, finding that some patients had symptoms resembling mycosis fungoides (MF), but with different histopathologic features.
- The findings suggest that while dupilumab can induce a benign lymphoid reaction that mimics CTCL, these changes are reversible and exhibit distinct histological characteristics.*
Article Synopsis
- Biological treatments are becoming vital for managing moderate-to-severe atopic dermatitis in children, with dupilumab and tralokinumab currently approved for use.
- Dupilumab has recently been extended for pediatric patients as young as six months, but details on its practical use for infants and young children are limited.
- There are ongoing concerns about the long-term effects and specific implementation challenges of biologicals in infants and preschoolers, highlighting a need for more research in this area.
Article Synopsis
- The study examines patient-centred dosing of dupilumab for atopic dermatitis (AD), focusing on its effectiveness and cost savings in daily practice.
- A total of 595 adult patients were assessed, with 401 managing to successfully taper their dupilumab treatment after controlling their eczema symptoms for over a year.
- Successful tapering was achieved in 83.3% of cases, suggesting that reducing medication frequency is both effective for patient health and economically beneficial, with estimated savings of nearly €4 million.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Celeste M Boesjes Liana F Van der Gang Nicolaas P A Zuithoff Daphne S Bakker Lotte S Spekhorst Marjolein S De Bruin-Weller
Acta Derm Venereol
February 2023
Article Synopsis
- Upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treating moderate-to-severe atopic dermatitis based on clinical trials, but more studies on its real-world application are needed.
- A prospective study involving 47 patients showed that after 16 weeks of treatment, 73% achieved a significant reduction in eczema severity, and 69% reported lower itch levels.
- While the treatment worked well for patients who had not responded to other medications, about 30% of participants discontinued due to ineffectiveness or side effects, with common issues including acne, herpes, nausea, and respiratory infections.
Background: Dupilumab has proven to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, few daily practice studies are available. The aim of this study is to evaluate the effect of 28 weeks dupilumab treatment on effectiveness, safety, and serum biomarkers in pediatric patients with moderate-to-severe AD in daily practice.
View Article and Find Full Text PDFArticle Synopsis
- Clinical trials indicate that baricitinib is an effective oral treatment for moderate-to-severe atopic dermatitis, though there's limited data from everyday clinical use.
- A multicenter study assessed the treatment's effectiveness and safety over 16 weeks in 51 adults, using various outcome measurements at multiple check-ins.
- Despite some positive outcomes, a significant number of patients (43.2%) stopped treatment due to ineffectiveness or side effects, highlighting the variability in effectiveness and safety in this patient group.
A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis.
Maartje M van de Meeberg Renske C F Hebing Michael T Nurmohamed Herma H Fidder Martijn W Heymans Marjolein S de Bruin-Weller
Br J Clin Pharmacol
January 2023
Article Synopsis
- * A meta-analysis of 25 studies found that higher MTX-PG levels in patients with rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis correlated with lower disease activity at various time points.
- * The results support the need for therapeutic drug monitoring (TDM) in clinical practice, indicating that individualized MTX dosing could improve the management of IMIDs by effectively reducing symptoms.
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
Lotte S Spekhorst Marlies de Graaf Floris Loeff Nicolaas P A Zuithoff Daphne Bakker Marjolein S de Bruin-Weller
JAMA Dermatol
December 2022
Article Synopsis
- The study focuses on patients with atopic dermatitis (AD) undergoing treatment with dupilumab, aiming to investigate the relationship between serum levels of dupilumab at 16 weeks and both treatment response and adverse effects.
- Conducted at the University Medical Center Utrecht, the research involved 295 adult patients treated according to a specific clinical protocol, excluding those who changed dosage or discontinued treatment early.
- Main outcomes included assessing disease severity using the Eczema Area and Severity Index (EASI) and analyzing treatment responses, with results gathered from January to June 2022.
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Lotte S Spekhorst Marlies de Graaf Nicolaas P A Zuithoff Juul M P A van den Reek Marijke Kamsteeg Marjolein S de Bruin-Weller
JAMA Dermatol
September 2022
Article Synopsis
- Long-term data on the survival of dupilumab in patients with atopic dermatitis (AD) is limited, and there is a need to understand what factors influence its effectiveness over time.
- The study analyzed data from 715 adult patients in the Netherlands, showing that dupilumab had drug survival rates of 90.3%, 85.9%, and 78.6% at 1, 2, and 3 years, respectively.
- Factors linked to shorter drug survival included the use of immunosuppressants and being a nonresponder at 4 weeks, as well as age over 65 and severe forms of AD, indicating specific characteristics that could predict treatment outcomes.
Article Synopsis
- A study was conducted to evaluate different dosing regimens of dupilumab for patients with controlled atopic dermatitis (AD), using a patient-centered approach, as no real-world studies existed on this topic.
- Ninety adult patients were divided into three groups based on their dupilumab dosing frequency, with results showing that disease severity scores remained stable despite changes in dosing intervals.
- Although some patients experienced a temporary increase in pruritus (itching), overall biomarkers and dupilumab serum levels indicated that dose reduction could be effective while maintaining low disease activity for those with controlled AD.
Article Synopsis
- The study used indirect treatment comparison to evaluate the effectiveness of baricitinib vs. dupilumab in adult patients with moderate-to-severe atopic dermatitis, focusing on approved doses.
- At weeks 4 and 16, baricitinib showed a greater improvement in itch scores than dupilumab, particularly in patients using it as monotherapy or alongside topical corticosteroids, though differences weren't as pronounced at week 16.
- Overall, baricitinib may provide faster relief from itching while maintaining similar levels of overall skin improvement and quality of life compared to dupilumab.